Epizyme Total Current Liabilities

Epizyme (EPZM) currently reports a total current liabilities of $35M as of June 2022. That compares with $41M in the prior-year period — down 14.5% year over year. Use the charts on this page to explore Epizyme's total current liabilities history and peer comparisons.

Epizyme's total current liabilities decreased from $41M to $35M — a 14.5% year-over-year decrease (period ending June 2022). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Epizyme reported $35M in total current liabilities as of June 2022. That compares with $41M in the prior-year period — down 14.5% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total current liabilities of $35M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Epizyme, and consider following EPZM for alerts when major investors trade the stock.

Epizyme is classified in the Healthcare sector. On total current liabilities, it currently shows $35M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing EPZM with unrelated industries.